<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT00097500 on 2008_09_30: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT00097500">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00097500">&#8593; Current version of this study</a></div><h1>View of NCT00097500 on
  2008_09_30</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT00097500</td>
</tr>
<tr>
<th>Updated:</th><td>2008_09_30</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>A Phase 3, Randomized, Open Label, Comparator Controlled, Parallel Group, Multicenter Study to Compare the Effects of Exenatide and Insulin Glargine on Beta Cell Function and Cardiovascular Risk Markers in Subjects With Type 2 Diabetes Treated With Metformin Who Have Not Achieved Target HbA1c</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus&reg; injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p></p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 3</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Randomized</td>
</tr>
<tr>
<th>Study design</th><td>Open Label</td>
</tr>
<tr>
<th>Study design</th><td>Active Control</td>
</tr>
<tr>
<th>Study design</th><td>Parallel Assignment</td>
</tr>
<tr>
<th>Study design</th><td>Safety/Efficacy Study</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: To compare beta-cell function after intensified therapy with exenatide or insulin glargine in subjects with type 2 diabetes treated with metformin.<br>Time Frame: 52 weeks<br>Safety Issue? No</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: To compare postprandial beta-cell function after long-term therapy with exenatide or insulin glargine in subjects with type 2 diabetes mellitus.<br>Time Frame: 122 weeks<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: To compare the effects of intensified therapy with exenatide or insulin glargine in subjects with type 2 diabetes treated with metformin with respect to various pharmacodynamic measurements as well as safety and tolerability.<br>Time Frame: 52 weeks<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: To compare the effects following cessation of intensified therapy with exenatide or insulin glargine in subjects with type 2 diabetes treated with metformin on various pharmacodynamic measurements.<br>Time Frame: 52 weeks<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: To compare the effects following cessation of long-term intensified therapy with exenatide or insulin glargine in subjects with type 2 diabetes treated with metformin on various pharmacodynamic measurements.<br>Time Frame: 122 weeks<br>Safety Issue? No</td>
</tr>
<tr>
<th>Condition</th><td>
         Type 2 Diabetes Mellitus
      </td>
</tr>
<tr>
<th>Arm/Group</th><td>
<div>Arm Label: 1      
            &nbsp; &nbsp; &nbsp; &nbsp;
        Experimental</div>
<p></p>
</td>
</tr>
<tr>
<th>Arm/Group</th><td>
<div>Arm Label: 2      
            &nbsp; &nbsp; &nbsp; &nbsp;
        Active Comparator</div>
<p></p>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: exenatide
            &nbsp; &nbsp; &nbsp; &nbsp;
            Arm Label: 1</div>
<p>subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets</p>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: Insulin glargine
            &nbsp; &nbsp; &nbsp; &nbsp;
            Arm Label: 2</div>
<p>subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets</p>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>Active, not recruiting</td>
</tr>
<tr>
<th>Start date</th><td>
         2004-09
      </td>
</tr>
<tr>
<th>Last follow-up date</th><td>
         2009-12
      
      (Anticipated)
  </td>
</tr>
<tr>
<th>Primary completion date</th><td>
         2009-12
      
      (Anticipated)
  </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>Inclusion Criteria:<br> &nbsp;- HbA1c between 6.6% and 9.5%, inclusive.<br> &nbsp;- Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive.<br> &nbsp;- Treated with a stable dose of metformin for at least 3 months prior to screening.<br>
<br>Exclusion Criteria:<br> &nbsp;- Patients previously in a study using exenatide.<br> &nbsp;- Treated with oral anti-diabetic medications other than metformin within 3 months of screening.<br> &nbsp;- Treated with insulin within 3 months of screening.</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Both
         </td>
</tr>
<tr>
<th>Minimum age</th><td>30 Years</td>
</tr>
<tr>
<th>Maximum age</th><td>75 Years</td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>Amylin Pharmaceuticals, Inc.</td>
</tr>
<tr>
<th>Organization study ID</th><td>2993-114</td>
</tr>
<tr>
<th>Sponsor</th><td>
               Amylin Pharmaceuticals, Inc.
            </td>
</tr>
<tr>
<th>Collaborator</th><td>
               Eli Lilly and Company
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               United States: Food and Drug Administration
         </td>
</tr>
<tr>
<th>Health Authority</th><td>
               Finland: National Agency for Medicines
         </td>
</tr>
<tr>
<th>Health Authority</th><td>
               Netherlands: Medicines Evaluation Board (MEB)
         </td>
</tr>
<tr>
<th>Health Authority</th><td>
               Sweden: Medical Products Agency
         </td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
